Skip to content

Cannabis research published in 2017

Page 4 of 4: studies 61 to 72 of 72, newest first. Back to the cannabis overview

Studies

Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Noro psikiyatri arsivi March 2017 Berker Duman, Nilay Sedes, Bora Baskak

Methylenedioxymethamphetamine (MDMA) is an amphetamine-derived psychostimulant, usually known as "ecstasy." The long-term neuropsychological effects of MDMA are examined in several studies with conflicting results. The most common findings reported are depression, anxiety, and memory and attention deficits. In addition to acute psychotic reactions observed after MDMA use, serotonergic and...

DOI: 10.5152/npa.2017.16964 (opens in new tab) Full text (opens in new tab) Psychotic disorders Substance-induced psychosis Substance-related disorders

Aleister Crowley on Drugs

International Journal for the Study of New Religions February 20, 2017 Christopher Partridge 1 citation

While much has been written about the life, work and influence of Aleister Crowley, relatively little attention has been directed to his drug use. This is a little surprising because, not only did he become addicted to heroin, but he incorporated psychoactive substances in his occult work, discussed their psychological effects, commented on drug-related social issues, critiqued contemporary...

Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta‐analysis

Acta Psychiatrica Scandinavica February 7, 2017 R. Carney, J. Cotter, J. Firth et al.

We aimed to assess whether individuals at ultra high risk (UHR) for psychosis have higher rates of cannabis use and cannabis use disorders (CUDs) than non‐UHR individuals and determine whether UHR cannabis users have more severe psychotic experiences than non‐users.

Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway.

European Neuropsychopharmacology February 2017 Stephanie M Todd, Cilla Zhou, David J Clarke et al.

The evidence base for the use of medical cannabis preparations containing specific ratios of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) is limited. While there is abundant data on acute interactions between CBD and THC, few studies have assessed the impact of their repeated co-administration. We previously reported that CBD inhibited or potentiated the acute effects of THC dependent on...

Altered subjective reward valuation among female heavy marijuana users.

Experimental and Clinical Psychopharmacology February 2017 Kathryn R. Hefner, Mark. J. Starr

Maladaptive decision-making is a cardinal feature of drug use, contributing to ongoing use, and reflecting alterations in how drug users assess uncertain reward value. Accumulating evidence indicates the consequences of heavy marijuana use are worse for female versus male animals and humans, but research assessing sex differences in reward-related decision-making among marijuana users remains...

Adolescent Cannabinoid Exposure Induces a Persistent Sub-Cortical Hyper-Dopaminergic State and Associated Molecular Adaptations in the Prefrontal Cortex.

Cerebral Cortex February 1, 2017 Justine Renard, Laura G Rosen, Michael Loureiro et al.

Considerable evidence suggests that adolescent exposure to delta-9-tetrahydrocanabinol (THC), the psychoactive component in marijuana, increases the risk of developing schizophrenia-related symptoms in early adulthood. In the present study, we used a combination of behavioral and molecular analyses with in vivo neuronal electrophysiology to compare the long-term effects of adolescent versus...

Sex differences in the subjective effects of oral Δ9-THC in cannabis users.

Pharmacology, Biochemistry, and Behavior January 2017 Jessica S Fogel, Thomas H Kelly, Philip M Westgate et al.

Previous studies suggest that there are sex differences in endocannabinoid function and the response to exogenous cannabinoids, though data from clinical studies comparing acute cannabinoid effects in men and women under controlled laboratory conditions are limited. To further explore these potential differences, data from 30 cannabis users (N=18 M, 12 F) who completed previous...

Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.

Current Topics in Behavioral Neurosciences 2017 Jenny L Wiley, Julie A. Marusich, Brian F Thomas

Originally developed as research tools for use in structure-activity relationship studies, synthetic cannabinoids contributed to significant scientific advances in the cannabinoid field. Unfortunately, a subset of these compounds was diverted for recreational use beginning in the early 2000s. As these compounds were banned, they were replaced with additional synthetic cannabinoids with...

Anatomy of a Joint: Comparing Self-Reported and Actual Dose of Cannabis and Tobacco in a Joint, and How These Are Influenced by Controlled Acute Administration

Cannabis and Cannabinoid Research 2017 Chandni Hindocha, Tom P. Freeman, Helen Valerie Curran 42 citations

Abstract Introduction: Major gaps exist in the measurement of cannabis exposure. The accuracy of self-reported cannabis and tobacco dose per joint is poorly characterized and has never been investigated following acute cannabis/tobacco exposure. Using an innovative “Roll a Joint” paradigm, this study aims to (1) compare estimated and actual dose of cannabis and tobacco per joint at baseline and...

A variant in the COMT gene and psychosis in youth who have used cannabis

ERA: Education and Research Archive 2017 David Rossolatos

Cannabis use is a known risk factor for the development of psychotic disorders. Clinical and preclinical genetic studies provide growing evidence that genes related to dopamine signalling and neuroprotection, like COMT, are implicated in the cannabis-psychosis association. Considering the burden of psychosis on society, as well as increasing use of cannabis among the teenage population due to...

SYNTHETIC CANNABIS OVERDOSE AND WITHDRAWAL IN A YOUNG ADULT: A CASE-REPORT AND COMMENTARY ON REGULATION

Journal of Addiction and Dependence 2017 John Samaan

Background/Introduction: Marijuana has been used for its psychotropic effects including enhanced relaxation and perceptual alterations. However, the use of synthetic cannabis (marijuana) leads to more frequent and drastic side effects than the typical use of regular marijuana, owing to the fact that synthetic cannabis has a shorter duration and an earlier peak of action. Despite all the...

Neurocognitive Correlates in Driving Under the Influence of Cannabis.

CNS & Neurological Disorders - Drug Targets 2017 Francesco P Busardò, Manuela Pellegrini, Julia Klein et al.

Delta (9)-tetrahydrocannabinol (THC) is the main psychoactive compound in cannabis and is frequently identified in blood samples from apprehended drivers suspected for driving under the influence of drugs. Changing social norms towards cannabis and higher acceptability towards the drug emphasize the need for in-depth understanding of the acute neurocognitive and psychomotor effects caused by...

DOI: 10.2174/1871527316666170424115455 (opens in new tab) Full text (opens in new tab) Cannabis Acute effects Chronic effects Delta 9-tetrahydrocannabinol +2